The Claim
In adults with overweight or obesity receiving tirzepatide, weekly administration of apitegromab at 10 mg/kg significantly reduces lean mass loss by 1.9 kg over 24 weeks compared to placebo, while total weight loss remains similar, indicating that selective myostatin inhibition can preserve skeletal muscle during pharmacologic weight loss.
What the research says
Supports is higher
Support is ahead, but a single strong opposing study can change this.
These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.
Among adults with overweight or obesity taking tirzepatide, weekly injections of apitegromab at 10 mg/kg reduce the loss of lean body mass by 1.9 kilograms over 24 weeks compared to placebo, without changing total weight loss.
See the scientific wording
In adults with overweight or obesity receiving tirzepatide, weekly administration of apitegromab at 10 mg/kg significantly reduces lean mass loss by 1.9 kg over 24 weeks compared to placebo, while total weight loss remains similar, indicating that selective myostatin inhibition can preserve skeletal muscle during pharmacologic weight loss.
A drug binds to an inactive form of a muscle-growth blocker, stopping it from becoming active. Without the active blocker, muscles stop breaking down and start building protein instead, so muscle mass stays the same even when the body loses fat.
What the research says
1 studyWhen people with extra weight take a weight-loss drug called tirzepatide, they often lose muscle too. This study found that adding another drug, apitegromab, helped them keep nearly 2 kilograms more muscle without changing how much total weight they lost.
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.